FDA highlights priority review vouchers redeemed as reauthorization lingers in Congressnews2024-01-22T19:29:18+00:00January 22nd, 2024|Endpoints News|
Bristol Myers outbid one company in limited interest for Karunanews2024-01-22T18:27:22+00:00January 22nd, 2024|Endpoints News|
Novartis’ TV ad for breast cancer drug Kisqali draws untitled letter from FDAnews2024-01-22T18:23:43+00:00January 22nd, 2024|Endpoints News|
In bid to extend cash runway, Cara to lay off workers, discontinue PhIII program in chronic kidney diseasenews2024-01-22T16:01:10+00:00January 22nd, 2024|Endpoints News|
Ionis touts PhIII success for rare disease drug amid company’s push to commercialize drugs independentlynews2024-01-22T16:00:57+00:00January 22nd, 2024|Endpoints News|
Sagimet’s positive PhIIb NASH data; FDA lifts hold on Pharvaris IND; Dianthus raises $230Mnews2024-01-22T15:46:16+00:00January 22nd, 2024|Endpoints News|
Roche ends Alzheimer’s partnership with AC Immune after lackluster datanews2024-01-22T15:28:00+00:00January 22nd, 2024|Endpoints News|
Trodelvy fails PhIII lung cancer study in blow to Gilead’s ADC expansion plansnews2024-01-22T13:44:08+00:00January 22nd, 2024|Endpoints News|
ArriVent outlines plans for $135M IPO in second biotech listing of 2024news2024-01-22T12:28:02+00:00January 22nd, 2024|Endpoints News|
LunaDNA, a connector of patients and pharmaceuticals, to shutternews2024-01-22T12:20:17+00:00January 22nd, 2024|Endpoints News|
